Oxaprozin

證據等級: L5

預測適應症: 10 個

Oxaprozin: From NSAID (Anti-Inflammatory/Analgesic Use) to Acromesomelic Dysplasia, Hunter-Thompson Type

One-Sentence Summary

Oxaprozin is a nonsteroidal anti-inflammatory drug (NSAID); detailed original indication and mechanism-of-action records are not available in this evidence pack, and the drug is not currently marketed in Taiwan/US per the data on file. The TxGNN model predicts a possible link to Acromesomelic Dysplasia, Hunter-Thompson Type, a rare genetic skeletal disorder, but this prediction is supported by 0 clinical trials and 0 publications — the model’s own rationale flags it as likely a false-positive knowledge graph association.

Quick Overview

Item	Content
Original Indication	Not on file (no Taiwan/US license record; per embedded rationale text, oxaprozin is an NSAID with COX-1/COX-2 inhibitory, analgesic/anti-inflammatory activity)
Predicted New Indication	Acromesomelic Dysplasia, Hunter-Thompson Type
TxGNN Prediction Score	99.98% (global rank 1140)
Evidence Level	L5 (model prediction only, no supporting trials or literature)
US Market Status	未上市 (Not Marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism-of-action data is not available for oxaprozin in this evidence pack (flagged as a High-severity data gap, DG002). Based on the information embedded in the model’s own rationale, oxaprozin is a conventional NSAID acting through COX-1/COX-2 inhibition to relieve pain and inflammation — the pharmacological basis typically applied to osteoarthritis, rheumatoid arthritis, and related joint disorders.

The top-ranked predicted indication, however, is Acromesomelic Dysplasia, Hunter-Thompson Type — a rare inherited skeletal dysplasia caused by GDF5 gene mutations, affecting limb development rather than active inflammation. The model’s own repurposing rationale explicitly states there is no biological mechanistic link between NSAID pharmacology and this disorder, and attributes the high score to likely noise from generic “skeletal/joint” node connections in the knowledge graph rather than a genuine pharmacological signal.

Among the 10 predicted indications reviewed, only two (rank 5: spondyloarthropathy susceptibility; rank 9: RF-positive polyarticular juvenile idiopathic arthritis) retain a plausible NSAID-relevant mechanism — but both still lack any clinical trial or literature support and were also scored L5/Hold. The remaining candidates (ranks 1–4, 6, 8, 10) are rare monogenic skeletal/developmental syndromes with no inflammatory component, and rank 7 (rheumatoid nodulosis) has only weak theoretical plausibility. None currently clear even the earliest evidentiary bar for further evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Oxaprozin is not currently marketed in Taiwan/US per the records available (market status: 未上市; total licenses: 0). No NDA or license entries are on file to summarize.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data are not currently available; the TFDA package insert lookup is flagged as a Blocking data gap, DG001, and must be resolved before any safety evaluation can proceed.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top-ranked prediction has a high TxGNN score but no clinical trial or literature support, and the model’s own rationale identifies it as a likely false-positive/noise association with no biological plausibility. Combined with the drug’s non-marketed status and missing MOA/safety data, there is currently no basis to advance any of the 10 predicted indications past initial screening.

To proceed, the following is needed:

TFDA package insert (warnings/contraindications) — Blocking gap, required before any safety-stage (S1) evaluation
Verified mechanism-of-action data via DrugBank API
Independent literature/preclinical search specifically for the two mechanistically plausible candidates (spondyloarthropathy susceptibility, RF-positive polyarticular JIA), since none currently exists in this evidence pack
Re-run TxGNN candidate screening with lower priority on rare monogenic skeletal syndromes lacking inflammatory pathophysiology, to reduce noise in future candidate lists
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.